CSL partners with AWS to apply AI, cloud tools in biopharma R&D

By Public Technologies
  • CSL entered a collaboration with AWS to apply AI and cloud tools across research and clinical development.
  • Partnership targets faster target identification, improved scientific data analysis, tighter lab-to-computation feedback, shorter R&D timelines.
  • Clinical workstream aims to cut manual effort in protocol authoring, data handling, regulatory submissions while maintaining governance, traceability, inspection readiness.
  • AWS will serve as principal AI and cloud provider, including Amazon Bedrock, providing infrastructure, tooling, technical expertise, workforce AI training.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSL Limited published the original content used to generate this news brief on September 28, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.